News stories about Atrion Corporation (NASDAQ:ATRI) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern rates the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Atrion Corporation earned a coverage optimism score of 0.09 on Accern’s scale. Accern also gave news headlines about the medical instruments supplier an impact score of 46.0736460709253 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Separately, BidaskClub upgraded shares of Atrion Corporation from a “buy” rating to a “strong-buy” rating in a research note on Thursday, June 29th.
Shares of Atrion Corporation (ATRI) traded up 0.14% on Wednesday, hitting $664.90. 4,275 shares of the stock were exchanged. The firm has a market cap of $1.23 billion, a price-to-earnings ratio of 37.25 and a beta of 0.92. The firm’s 50 day moving average price is $651.26 and its 200 day moving average price is $589.49. Atrion Corporation has a one year low of $418.00 and a one year high of $694.00.
Atrion Corporation (NASDAQ:ATRI) last released its quarterly earnings data on Tuesday, August 8th. The medical instruments supplier reported $5.40 earnings per share for the quarter. Atrion Corporation had a net margin of 22.75% and a return on equity of 18.67%. The business had revenue of $36.16 million for the quarter. Equities analysts anticipate that Atrion Corporation will post $9.90 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which was paid on Friday, September 29th. Investors of record on Friday, September 15th were issued a $1.20 dividend. This represents a $4.80 dividend on an annualized basis and a dividend yield of 0.72%. The ex-dividend date of this dividend was Thursday, September 14th. This is a boost from Atrion Corporation’s previous quarterly dividend of $1.05. Atrion Corporation’s dividend payout ratio (DPR) is 26.88%.
In related news, Chairman Emile A. Battat sold 1,408 shares of the stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $652.91, for a total value of $919,297.28. Following the sale, the chairman now owns 148,881 shares of the company’s stock, valued at approximately $97,205,893.71. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 24.23% of the stock is owned by company insiders.
COPYRIGHT VIOLATION WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Impact Atrion Corporation (ATRI) Share Price” was first posted by Markets Daily and is owned by of Markets Daily. If you are accessing this news story on another site, it was illegally copied and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this news story can be read at https://www.themarketsdaily.com/2017/10/11/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-atrion-corporation-atri-share-price.html.
Atrion Corporation Company Profile
Atrion Corporation (Atrion) is engaged in developing and manufacturing products, primarily for medical applications. The Company’s medical products range from fluid delivery devices to ophthalmic and cardiovascular products. Its fluid delivery products include valves that promote infection control and needle safety.
Receive News & Ratings for Atrion Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion Corporation and related companies with MarketBeat.com's FREE daily email newsletter.